君實生物(688180.SH):JS103注射液獲批臨牀試驗
格隆匯5月12日丨君實生物(688180.SH)公佈,近日,公司收到國家藥品監督管理局核准簽發的《藥物臨牀試驗批准通知書》,JS103注射液(項目代號“JS103”)的臨牀試驗申請獲得批准。
JS103是公司自主研發的聚乙二醇化尿酸酶衍生物,主要用於高尿酸血癥伴或不伴有痛風的治療,其可通過催化尿酸氧化成溶解度顯著高於尿酸的尿囊素,從而達到降低血尿酸的作用。高尿酸血癥是由於嘌呤代謝紊亂產生過量尿酸或尿酸排泄受阻,引起血液中尿酸超過臨界值而形成的代謝異常綜合徵。痛風是單鈉尿酸鹽沉積所致的晶體相關性關節病,與高尿酸血癥直接相關。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.